Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-06-30FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
The FDA approved a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADBM from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2023-06-14FDA Approved: ABRILADA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for ABRILADA (adalimumab-afzb) submitted by Pfizer Laboratories Div Pfizer Inc to update the labelin…
-
FDA approval · 2023-05-23FDA Approved: ADALIMUMAB — Original Application (CELLTRION USA, Inc.)
FDA approved ADALIMUMAB-AATY from CELLTRION USA, Inc. as a biosimilar to adalimumab under an Original Application for the same indications a…
-
FDA approval · 2023-05-18FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for ADALIMUMAB-ADBM, a biosimilar to adalimumab, from QUALLENT PHARMACEUTICALS HEALTH LLC.
-
FDA approval · 2023-04-25FDA Approved: TAZAROTENE — Original Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved the original ANDA for tazarotene (TAZAROTENE) by Padagis Israel Pharmaceuticals Ltd.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-04-14FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for adalimumab-adaz, a biosimilar to adalimumab, confirming its regulatory approval for use.
-
FDA approval · 2023-03-31FDA Approved: YUSIMRY — Supplemental Application (Coherus BioSciences Inc)
FDA approved a supplemental Biologics License Application for YUSIMRY (adalimumab-aqvh) by Coherus BioSciences, authorizing the biosimilar p…
-
FDA approval · 2023-03-20FDA Approved: TAZAROTENE — Original Application (Solaris Pharma Corporation)
The FDA approved a generic version of tazarotene (topical retinoid) from Solaris Pharma Corporation through an Original Abbreviated New Drug…
-
FDA approval · 2023-03-06FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab (Stelara) to expand its indications, as requested by Janssen Biotech, Inc.
-
FDA approval · 2022-12-19FDA Approved: ILUMYA — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for ILUMYA (tildrakizumab) from Sun Pharmaceutical Industries, Inc., supporting a regulatory upd…
-
FDA approval · 2022-12-13FDA Approved: IDACIO — Original Application (Fresenius Kabi USA, LLC)
FDA approved IDACIO (adalimumab-afcf) from Fresenius Kabi USA, LLC as a biosimilar to adalimumab (Humira) under an original Biologics Licens…
-
FDA approval · 2022-09-13FDA Approved: TAZAROTENE — Original Application (Cosette Pharmaceuticals, Inc.)
FDA approved Cosette Pharmaceuticals' generic tazarotene through an Original Application (ANDA 215433). The product is intended for the trea…
-
FDA approval · 2022-09-09FDA Approved: SOTYKTU — Original Application (E.R. Squibb & Sons, L.L.C.)
FDA approved SOTYKTU (deucravacitinib) from its original application (NDA214958) by E.R. Squibb & Sons, L.L.C. for the treatment of plaque p…
-
FDA approval · 2022-07-29FDA Approved: ZORYVE — Original Application (Arcutis Biotherapeutics, Inc.)
The FDA approved ZORYVE (roflumilast) under an original application for topical treatment of plaque psoriasis.
-
FDA approval · 2022-07-18FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
The FDA approved Sandoz's supplemental application for the adalimumab biosimilar ADALIMUMAB-ADAZ. The approval covers multiple inflammatory …
-
FDA approval · 2022-06-17FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
The FDA approved a supplemental application for Enbrel (etanercept) from Immunex Corporation, resulting in labeling changes for the product.…
-
FDA approval · 2022-06-16FDA Approved: SKYRIZI — Original Application (AbbVie Inc.)
FDA approved SKYRIZI (risankizumab-rzaa) from AbbVie in an original Biologics License Application. The approval covers adults with plaque ps…
-
FDA approval · 2022-06-14FDA Approved: SILIQ — Supplemental Application (Bausch Health US LLC)
FDA approved a supplemental application for SILIQ (brodalumab) submitted by Bausch Health US LLC.
-
FDA approval · 2022-05-31FDA Approved: FLUOCINOLONE ACETONIDE OIL — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Fluocinonide Acetonide Oil from Rising Pharma Holdings, Inc., a topical corticosteroid produ…
-
FDA approval · 2022-05-23FDA Approved: VTAMA — Original Application (Organon LLC)
The FDA approved VTAMA (tapinarof) from Organon LLC in its original application for the treatment of plaque psoriasis in adults.
-
FDA approval · 2022-02-17FDA Approved: CLOBETASOL PROPIONATE — Original Application (Quagen Pharmaceuticals LLC)
FDA approved the original application for a generic clobetasol propionate topical product by Quagen Pharmaceuticals LLC.
-
FDA approval · 2021-12-17FDA Approved: YUSIMRY — Original Application (Coherus BioSciences Inc)
FDA approved YUSIMRY (adalimumab-aqvh) from Coherus BioSciences in an original biologics license application, likely as a biosimilar to adal…
-
FDA approval · 2021-12-14FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc. The submission status …
-
FDA approval · 2021-10-15FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approves a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADBM from Quallent Pharmaceuticals Health LLC. The approval…
-
FDA approval · 2021-06-17FDA Approved: INFLECTRA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves a supplemental application for INFLECTRA (infliximab-dyyb) from Pfizer Laboratories Div Pfizer Inc, marking FDA action on a bio…